For Healthcare Professionals

STOP to consider

The only 2.5% hydrocortisone steroid solution available*

DROP to provide a clear topical solution

Class 7, low-potency corticosteroid with specially designed dosing applicator

GO with added features and benefits

Developed for patient adaptability

*FDA Orange Book, December 2023.
†To be used for illustrative purposes only. Individual dose will vary by patient and condition.
‡Use language required by state: D.A.W. (dispense as written), B.M.N. (brand medically necessary), or D.N.S. (do not substitute).

Mission Pharmacal Company
San Antonio, TX 78230-1355
(210) 696-8400
This material is intended to provide basic information and is not medical advice. All medical advice, diagnosis, and treatment should be obtained from your physician. The product information provided in this site is intended for residents of the United States.

Copyright © Mission Pharmacal Company. All rights reserved.
Important Safety Information:
Expand Close

INDICATIONS:
Texacort® (hydrocortisone) topical solution 2.5% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Important Safety Information

CONTRAINDICATIONS:
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS:

  • Systemic absorption of topical corticosteroids can cause reversible hypothalamic-pituitary-adrenocortical (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glycosuria in some patients.
  • Conditions which augment systemic absorption include: application of the more potent steroids, use over large surface areas, prolonged use, or the addition of occlusive dressings. In these cases, patients should be evaluated periodically for HPA axis suppression using urine free cortisol and ACTH stimulation tests.
  • If HPA axis suppression is noted, attempt to withdraw or decrease the frequency of the drug, or substitute a less potent steroid.
  • Upon drug discontinuation, recovery of HPA axis function is generally prompt and complete; infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
  • Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to HPA axis suppression, Cushing’s syndrome, and intracranial hypertension. Limit topical corticosteroids to the least effective amount. Chronic corticosteroid therapy can interfere with growth and development in children.
  • If irritation develops, discontinue use and institute appropriate therapy.
  • In the presence of skin infections, an appropriate antimicrobial agent should be instituted. Discontinue the corticosteroid if a favorable response does not occur promptly, until the infection has been adequately controlled.

ADVERSE REACTIONS:
The following local adverse reactions (in order of decreasing frequency) are reported infrequently with topical corticosteroids (but may occur more frequently with occlusive dressings): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

Please click here for full Prescribing Information. 

ARE YOU A HEALTHCARE PROFESSIONAL?

The information in the following section is intended for US Healthcare
Professionals only.

< No, take me back
Yes, I am a Healthcare Professional >